Taper Or Abrupt Steroid Stop: TOASSTtrial (TOASST)
Brief Summary
This study is an Investigator-initiated, placebo-controlled, multicenter noninferiority trial, comparing rapid termination of systemic glucocorticoid treatment with a tapering regime over 4 weeks.
Detailed Description
In total, 530 patients will be enrolled. Patients will be randomly assigned in a 1:1 ratio to either prednisone in decreasing doses over 4 weeks or placebo.
Patients, treating physicians, and study personnel will be blinded to treatment allocation to either prednisone or matching placebo. At inclusion, we will perform a 250 micrograms Synacthen® stimulation test. The results of the test will be blinded to treating physicians and investigators, and its value to predict clinical outcome will only be assessed after completion of the trial. As a safety measure, all patients will be instructed about stress coverage as well as signs and symptoms of hypocortisolism and will be provided with emergency medication. Patients will be randomized to the standard (tapering) or the experimental (matching placebo) arm. Follow-up will be for six months. In order to improve adherence to the study and ensure feasibility, follow-up visits in most study centers will be by telephone only. Visits will be performed early after stopping glucocorticoids in both arms (i.e. at days 7 and 35) to ensure safety; the other two visits will be on days 90 and 180.
Amendment approved in 1-2018: former exclusion criterion 'status post organ transplantation' was revised and deleted
Intervention / Treatment
Study Design
Treatment
Randomized
Parallel Assignment
Standard treatment arm: Prednisone, a synthetic glucocorticoid with intermediate duration of action (biological half-life 18-35 hrs). The detailed characteristics of the compound, marketed under several brand names, can be found at www.swissmedicinfo.ch: Prednison Streuli (Swissmedic registration number: 29349); Prednison Axapharm (Swissmedic registration number: 58761); Prednison Galepharm (Swissmedic registration number: 50821).
Interventional treatment arm: matching placebo.
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Blinding of trial participants, treating physicians, study doctors, study nurses, outcome assessors and data analysts will be ensured by using identical-looking placebo, packaged in identical vials as the prednisone verum. Vials will be labeled with "Prednisone or Placebo" in an identical fashion.
Arm Groups
Placebo Comparator: Placebo arm (intervention arm)
Stop glucocorticoid treatment; administer placebo matching the verum preparation in weekly intervals.
Active Comparator: Verum group (control/standard arm)
If patient is on > 7.5 mg prednisone-equivalent daily: administer 7.5 mg q.d. for 7 days, then 5 mg q.d. for 7 days, then 2.5 mg q.d. for 7 days, then 2.5 mg q.d. every second day, then stop. If patient on 7.5 mg q.d.: maintain for 7 days, then taper as above.
Eligibility Criteria
- Informed Consent as documented by signature (Appendix Informed Consent Form)
- Age ≥ 18 years
- Daily glucocorticoid dose ≥ 7.5 mg prednisone-equivalent at the time of inclusion
- Therapy over ≥ 28 days, ≥ 7.5 mg average daily dose, with a cumulative glucocorticoid dose ≥ 420 mg prednisone-equivalent prior to inclusion
- Tapering not or no longer mandatory to treat underlying disease
- Primary adrenal failure
- Treatment with systemic depot glucocorticoids (e.g. intramuscular, epidural)
- Incapacity to administer glucocorticoid cover treatment in situations of stress
- Inability or unwillingness to provide informed consent
- Women who are pregnant or breast feeding,
- Intention to become pregnant during the course of the study,
- Lack of safe contraception, defined as: Female participants of childbearing potential,
not using and not willing to continue using a medically reliable method of contraception
for the entire study duration, such as oral, injectable, or implantable contraceptives,
or intrauterine contraceptive devices, or who are not using any other method considered
sufficiently reliable by the investigator in individual cases. - Known or suspected non-compliance
- Inability to follow the procedures of the study, e.g. due to language problems,
psychological disorders, dementia, etc. of the participant, - Participation in another study with investigational drug within the 30 days preceding and
during the present study, - Previous enrolment into the current study,
- Enrolment of the investigator, his/her family members, employees and other dependent persons
Outcome Measures
Time to any incidence
Time to first occurrence of hospitalization, death, initiation of unplanned systemic glucocorticoid therapy, or adrenal crisis (defined as glucocorticoid-responsive hypotension or shock with or without accompanying symptoms and signs such as weakness, apathy, nausea, vomiting, abdominal pain, hypothermia, hyponatremia [serum sodium < 135 millimole (mM)], hyperkalemia [serum potassium > 5 mM], hypoglycemia [plasma glucose < 3.5 mM]); whichever occurs first.
up to 6 months
Time to specific incidence
Time to first occurrence of individual components of the primary outcome;
up to 6 months
Cumulative overall systemic glucocorticoid dose
Cumulative overall systemic glucocorticoid dose
up to 6 months
Cumulative systemic glucocorticoid dose administered to treat or prevent adrenal failure
Cumulative systemic glucocorticoid dose administered to treat or prevent adrenal failure
up to 6 months
Cumulative systemic glucocorticoid dose administered to treat relapse
Cumulative systemic glucocorticoid dose administered to treat relapse of disease, specified for each disease
up to 6 months
General health status
General health status as self-assessed by the participant on a visual analog scale (VAS) from 0 to 100
assessed at days 1, 7, 28, 35, 90,180
Score of symptoms and signs of hypocortisolism
Score of symptoms and signs of hypocortisolism: weakness, hypothermia, nausea, vomiting, abdominal pain, fatigue, dizziness, Blood pressure, serum Na and serum glucose concentrations.
up to 6 months
Performance in 250 mcg Synacthen® test
Performance in 250 mcg Synacthen® test: test assessed day 1 in all participants, plus days 7 and 35 in those followed in centers Bruderholz, Luzern, Aarau
up to 6 months0
In patients hospitalized at study entry: length of hospital stay
In patients hospitalized at study entry: length of hospital stay
up to 6 months
Where is this study conducted?
We provide these clinical trial listings as a free service to the medical community based on public information sourced from ClinicalTrials.gov. We do not charge any fees for posting these types of trials. Please be aware that we are not responsible for the information displayed, as it is based on external public records.